Regeneron Pharmaceuticals, Inc. (REGN) Q3 Revenue Up 36%, Non-GAAP EPS Up 70%
Regeneron Pharmaceuticals (REGN) reported Q3 2026 revenues up 36% YoY to $5.1B, driven by Dupixent, EYLEA HD, and Libtayo. Non-GAAP EPS rose 70% to $20.07. The company expanded its Sanofi collaboration, receiving $1B upfront with potential for $7B in future milestones. The FDA approved Pasatru for FOP.
How this was made
The 30-second read
Why it matters
The earnings beat and pipeline progress are likely to lift Regeneron and may boost sentiment in the broader biotech sector.
Market read
First‑report earnings with material growth numbers; high trading relevance for short‑term positioning.
What to watch
Potential headwinds from competition in eye‑care and oncology markets, and reliance on Sanofi partnership milestones.
Background
Regeneron posted its Q3 2026 earnings, highlighting double‑digit growth across key products and a new FDA approval.
Ticker impact
Q3 2026 earnings released showing 36% revenue growth and 70% non‑GAAP EPS increase, plus new FDA approval and expanded Sanofi collaboration.
upward pressure as investors price in higher revenue and EPS growth
Revenue and EPS beat expectations, new collaboration revenue and FDA approval signal continued momentum.
Market effects
Biotech and pharma sector may see broader uplift from Regeneron's strong results and Sanofi partnership.
U.S. biotech stocks could rally in early trading.
Positive signal for global pharma collaborations and pipeline progress.
Counterpoint
If guidance falls short of market expectations or R&D spend spikes, the rally could be limited.
Key entities
- companyRegeneron Pharmaceuticals, Inc.
Biotech firm reporting Q3 2026 results.
- companySanofi
Partner in collaboration generating up‑front and milestone payments.
